Last updated: August 17, 2023
Sponsor: HaEmek Medical Center, Israel
Overall Status: Active - Recruiting
Phase
N/A
Condition
N/ATreatment
exofin®
Clinical Study ID
NCT03983343
0039-19-EMC
Ages 18-45 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Women aged 18-45.
- Term birth (> 37.0 weeks).
- Perineal tears grade 1 or 2, or episiotomy.
Exclusion
Exclusion Criteria:
- Perineal tears grades 3 or 4.
- Operative vaginal deliveries.
- Significant background diseases that can affect pain or recovery time: Pregestationaldiabetes mellitus, any heart disease, severe pulmonary disease, collagen or connectivetissue disease, rheumatic diseases, autoimmune diseases, known immunodeficiency andchronic steroid use.
- Signs of local infection prior to the beginning of repair of the tear.
- Known allergy to exofin®.
- Pregestational body mass index > 35 kg/m2.
- Women with excessive bleeding that does not allow the use of glue.
- Delivery of a dead fetus.
Study Design
Total Participants: 182
Treatment Group(s): 1
Primary Treatment: exofin®
Phase:
Study Start date:
October 01, 2019
Estimated Completion Date:
August 01, 2024
Study Description
Connect with a study center
EMEK Medical center
Afula, 1834111
IsraelActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.